ALT-803: Phase I/II started

Altor began an open-label, dose-escalation, U.S. Phase I/II trial to evaluate IV ALT-803 given on days 1, 8, 15 and 22 of a 6-week cycle for up to 4 cycles in about 50 patients. Shenzhen Beike has rig...